Telitacicept

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

About Vor Biopharma

Vor Biopharma is pioneering a new approach to autoimmune disease by targeting the upstream drivers of B cell dysfunction with its lead asset, telitacicept. The company has a validated path forward, with telitacicept already approved and marketed for three indications in China and a broad global pipeline targeting over a million potential patients in the US alone. Led by an experienced team, Vor Bio is positioned to become a global leader in targeted autoimmune therapeutics, moving beyond symptom control to deliver durable, disease-modifying benefits.

Therapeutic Areas